A new FDA advisory panel meeting, influenced by RFK Jr.'s push for broader access, will weigh the potential benefits and risks of widely promoted peptides. Click the link in bio to read The Blacklisting of Peptides You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category Empower 503B Outsourcing Facility Serving Retail Pharmacies Pharmacy Purchasing & Products Magazine Why the FDA Is Paying More Attention to 503A & 503B Pharmacies If you've been watching the compounding space, especially around GLP 1s and peptides, you've probably noticed something. The FDA is paying